Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206227 · ClinicalTrials.gov registry record · Early Phase 1
Histamine as a Molecular Transducer of Adaptation to Exercise
A Early Phase 1 study of Post-Exercise Hypotension, sponsored by University of Oregon.
- Active
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05206227: Active Early Phase 1 study of Post-Exercise Hypotension, sponsored by University of Oregon.
NCT05206227 is a Early Phase 1 study of Post-Exercise Hypotension that is active but no longer recruiting, run by University of Oregon. The registered enrollment target is 80 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05206227, a Early Phase 1 study of Post-Exercise Hypotension, is active but no longer recruiting, sponsored by University of Oregon.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating the role of histamine in generating adaptation to exercise
Primary Outcome
Beta-hexosaminidase release from mast cells in mast cell degranulation bioassay when exposed to intramuscular dialysate from exercising individuals
Conditions Studied
Interventions
- BEHAVIORAL Aerobic Exercise
- DRUG Antihistamine
- DRUG alpha-FMH
- BEHAVIORAL Resistance and Aerobic Exercise
Study Locations (1)
Oregon
- University of Oregon - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
What the registry record for NCT05206227 still lists
NCT05206227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher).
The record links to 1 condition, with Post-Exercise Hypotension appearing as the primary indexed condition, and to 4 interventions - of which Aerobic Exercise is the first listed.
NCT05206227 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05206227 about?
NCT05206227 is a clinical study titled "Histamine as a Molecular Transducer of Adaptation to Exercise". This study is investigating the role of histamine in generating adaptation to exercise
What is the current status of trial NCT05206227?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2021-07-28. Estimated completion is 2027-03-31.
What conditions does trial NCT05206227 study?
This clinical trial studies the following conditions: Post-Exercise Hypotension.
What interventions are being tested in trial NCT05206227?
The interventions under investigation include: Aerobic Exercise (BEHAVIORAL), Antihistamine (DRUG), alpha-FMH (DRUG), Resistance and Aerobic Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT05206227?
This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206227 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-Exercise Hypotension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05206227's enrollment target sits among peer trials
80 271st of 2000 higher than 1,704 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI